Repligen (NASDAQ:RGEN) Releases FY 2026 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.930-2.010 for the period, compared to the consensus estimate of 2.060. The company issued revenue guidance of $810.0 million-$840.0 million, compared to the consensus revenue estimate of $822.8 million.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday. Barclays raised their price target on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Wells Fargo & Company boosted their price objective on Repligen from $175.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. Finally, Canaccord Genuity Group lifted their price target on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and an average price target of $177.92.

Repligen Trading Down 3.2%

Repligen stock traded down $4.33 during mid-day trading on Wednesday, hitting $130.34. The stock had a trading volume of 214,821 shares, compared to its average volume of 750,444. The stock has a 50-day simple moving average of $155.83 and a two-hundred day simple moving average of $146.87. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.34 billion, a PE ratio of 6,599.95, a P/E/G ratio of 2.47 and a beta of 1.13. Repligen has a 12 month low of $102.96 and a 12 month high of $175.77.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The company’s revenue was up 18.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, sell-side analysts forecast that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Key Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q4 beat — Repligen reported $0.49 EPS vs. $0.44 expected and revenue of $197.9M vs. ~$192M expected; revenue rose ~18% year-over-year, showing demand recovery in bioprocessing. Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
• Positive Sentiment: Balance sheet strength — low leverage (debt/equity ~0.26) and strong liquidity (quick ratio ~7.1, current ratio ~8.4) provide flexibility to invest in growth or weather near-term variability. (Company financials/filings)
• Neutral Sentiment: Analyst divergence — TD Cowen reiterated a Buy and $200 PT, citing derisked upside despite cautious guidance. Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating
• Neutral Sentiment: Mixed analyst stance — Canaccord maintained a Hold with a $165 PT, noting solid execution but limited near-term upside at current valuation. Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
• Negative Sentiment: Cautious FY2026 guidance — company guided EPS of $1.93–$2.01 and revenue $810–$840M, below consensus EPS (~$2.06) and near the revenue consensus; the conservative guide trimmed expectations for 2026 growth. Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
• Negative Sentiment: Market reaction — several outlets note the sell-off following the cautious guide despite the beat; lower near-term upside and premium valuation made the guidance miss more impactful. Why Repligen Corporation’s (RGEN) Stock Is Down 6.43%

Institutional Investors Weigh In On Repligen

Several hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in shares of Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares in the last quarter. United Capital Financial Advisors LLC acquired a new position in Repligen in the third quarter valued at about $368,387,000. Opti Capital Management LP bought a new stake in shares of Repligen in the fourth quarter worth about $2,399,209,000. Invesco Ltd. increased its holdings in shares of Repligen by 43.9% in the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock worth $205,880,000 after acquiring an additional 383,399 shares in the last quarter. Finally, RTW Investments LP acquired a new stake in shares of Repligen during the fourth quarter worth about $174,347,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.